S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
Log in
NYSE:ARA

American Renal Associates Short Interest Ratio and Short Volume

Notice: This company has been marked as potentially delisted and may not be actively trading.
$11.52
+0.02 (+0.17 %)
(As of 01/25/2021)
Add
Compare
Today's Range
$11.52
Now: $11.52
$11.52
50-Day Range
$11.46
MA: $11.50
$11.52
52-Week Range
$5.57
Now: $11.52
$11.98
Volume9,800 shs
Average Volume106,940 shs
Market Capitalization$397.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11

Short Interest

American Renal Associates (NYSE:ARA) Short Interest Data

Current Short Volume1,040,000 shares
Previous Short Volume1,230,000 shares
Change Vs. Previous Month:-15.45%
Dollar Volume Sold Short$11.93 million
Short Interest Ratio / Days to Cover5.3
Last Record DateDecember, 31 2020
Outstanding Shares32,520,000 shares
Float Size31,610,000 shares
Short Percent of Float3.29%
Today's Trading Volume9,800 shares
Average Trading Volume106,940 shares
Today's Volume Vs. Average-90.84%

Short Interest Over Time


American Renal Associates (NYSE:ARA) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
12/31/20201,040,000 shares $11.93 million -15.5%3.3%5.3 $11.47
12/15/20201,040,000 shares $11.91 million -15.5%3.3%5.3 $11.45
11/30/20201,230,000 shares $14.07 million +144.2%3.9%7.1 $11.44
11/15/2020503,600 shares $5.75 million -6.8%1.6%3.1 $11.41
10/30/2020540,100 shares $6.17 million -11.9%1.7%3.9 $11.42
10/15/2020612,800 shares $6.99 million -24.6%1.9%4.6 $11.41
9/30/2020813,100 shares $9.38 million -3.0%2.6%6.5 $11.53
9/15/2020838,400 shares $5.24 million +8.3%2.7%11.1 $6.25
8/31/2020774,100 shares $4.94 million -8.4%2.5%9.4 $6.38
8/14/2020845,300 shares $5.69 million -9.5%2.7%9.3 $6.73
7/31/2020934,300 shares $6.79 million -15.1%3.0%9.8 $7.27
7/15/20201,100,000 shares $7.10 million -6.8%3.6%11 $6.45
6/30/20201,180,000 shares $7.53 million -4.1%3.8%11.1 $6.38
6/15/20201,230,000 shares $8.08 million +4.2%4.0%11.9 $6.57
5/29/20201,180,000 shares $6.89 million -2.5%3.8%10.4 $5.84
5/15/20201,210,000 shares $7.49 million -6.9%3.8%10.7 $6.19
4/30/20201,300,000 shares $8.13 million +4.8%4.2%12.4 $6.25
4/15/20201,240,000 shares $9.14 million -5.3%4.0%11.8 $7.37
3/31/20201,310,000 shares $9.33 million -10.8%4.3%13.3 $7.12
3/13/20201,468,900 shares $10.49 million -5.8%10.8%18.5 $7.14
2/28/20201,560,000 shares $12.43 million -3.1%5.1%19.6 $7.97
2/14/20201,610,000 shares $12.96 million +1.9%5.2%18.6 $8.05
1/31/20201,580,000 shares $13.21 million -1.9%5.1%14.4 $8.36
1/15/20201,610,000 shares $14.75 million -0.6%5.2%12 $9.16
12/31/20191,620,000 shares $15.91 million +1.9%5.3%11.5 $9.82

American Renal Associates (NYSE:ARA) Short Interest FAQ

speech bubbles
speech bubbles











What is American Renal Associates' current short interest?

Short interest is the volume of American Renal Associates shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 1,040,000 shares of ARA short. 3.29% of American Renal Associates' shares are currently sold short. View details.

What is a good short interest ratio for American Renal Associates?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. American Renal Associates currently has a short interest ratio of 5.0.

What is a good short interest percentage for American Renal Associates?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.29% of American Renal Associates' floating shares are currently sold short.

Is American Renal Associates' short interest increasing or decreasing?

American Renal Associates saw a decrease in short interest in December. As of December 31st, there was short interest totaling 1,040,000 shares, a decrease of 15.4% from the previous total of 1,230,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is American Renal Associates' float size?

American Renal Associates currently has issued a total of 34,543,000 shares. Some of American Renal Associates' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. American Renal Associates currently has a public float of 31,610,000 shares.

How does American Renal Associates' short interest compare to its competitors?

3.29% of American Renal Associates' shares are currently sold short. Here is how the short interest of companies in the industry of "miscellaneous health & allied services, not elsewhere classified" compare to American Renal Associates: Tivity Health, Inc. (18.92%), Ontrak, Inc. (39.81%), Viemed Healthcare, Inc. (3.89%), Baudax Bio, Inc. (4.85%), Cryo-Cell International, Inc. (0.00%), Emmaus Life Sciences, Inc. (0.00%), Caladrius Biosciences, Inc. (0.00%), Curative Biotechnology, Inc. (0.00%), BioRestorative Therapies, Inc. (0.00%), and American Caresource Holdings, Inc. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($5.18 billion), ViacomCBS Inc. ($4.71 billion), Analog Devices, Inc. ($4.45 billion), Aon Plc ($4.28 billion), Snap Inc. ($3.70 billion), Moderna, Inc. ($3.00 billion), The Clorox Company ($2.46 billion), Peloton Interactive, Inc. ($2.40 billion), The Kroger Co. ($2.38 billion), and Expedia Group, Inc. ($2.37 billion). View all of the most shorted stocks.

What does it mean to sell short American Renal Associates stock?

Short selling ARA is an investing strategy that aims to generate trading profit from American Renal Associates as its price is falling. American Renal Associates' stock is trading up $0.02 today. To short American Renal Associates stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that American Renal Associates will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against American Renal Associates?

A short squeeze for American Renal Associates occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ARA, which in turn drives the price of the stock up even further.

How often is American Renal Associates' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARA, twice per month. The most recent reporting period available is December, 31 2020.



This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.